Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

Inclusion Criteria: * Patients must have a pathologically confirmed diagnosis of DLBCL (including DLBCL not otherwise specified \[NOS\], DLBCL germinal center B-cell \[GCB\] type, DLBCL activated B cell \[ABC\]/non-GCB type, T cell/histiocyte-rich large B cell lymphoma, high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high-grade B cell lymphoma NOS). NOTE: DLBCL transformed from low-grade lymphoma among treatment-naive patients or patients previously treated with a non-anthracycline containing regimen are permitted * Patients may have completed the first cycle of R-CHOP (off study not combined with TAK-659) =\< 21 days prior to the first dose of TAK-659 or plan to receive the first cycle of R-CHOP after registration * Patients must have at least one high-risk feature, including: * ABC/non-GCB subtype determined by gene expression profiling or Hans algorithm by immunohistochemistry per treating institution standards * High-intermediate or high-risk group by National Comprehensive Cancer Network - International Prognostic Index (NCCN-IPI) with score \>= 4, at time of diagnosis * MYC gene rearrangement (by \[fluorescent in situ hybridization\] FISH) * MYC overexpression by immunohistochemistry (IHC) (\>= 40%) and BLC2 overexpression by IHC (\>= 50%) or * Previously treated transformed low-grade lymphoma to large B cell lymphoma with prior treatment not including an anthracycline * NOTE: BCL2 and/or BCL6 aberrancy are not required for enr…